Analyst consensus rating
Nektar Therapeutics Analyst Rating: Strong Buy
NKTR is rated Strong Buy by 10 analysts with a $144.40 target. As of 2026-08-30.
Direct answer
Nektar Therapeutics's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $144.40.
Forecast evidence checked August 30, 2026.
Get free Nektar Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $72.52
- Average price target
- $144.40
- High price target
- $192.00
- Low price target
- $65.00
- Low target gap
- -10.4%
- Target upside
- +99.1%
- High target gap
- +164.8%
- Target range width
- 175.1%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Nektar Therapeutics?
Nektar Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $144.40.
How far are Nektar Therapeutics's low and high targets from the recorded price?
The low target implies -10.4%, while the high target implies +164.8%.
How many analysts are included in Nektar Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Nektar Therapeutics's target upside or downside calculated?
The average target of $144.40 is divided by the recorded price of $72.52, then one is subtracted to produce +99.1%. This does not guarantee a future return.
When was Nektar Therapeutics's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.